Genetic neuromuscular diseases are a diverse group of disorders caused by mutations that impact muscle fibers, motor neurons, and neuromuscular junctions. Notable examples of these disorders include Duchenne muscular dystrophy (DMD), spinal muscular atrophy (SMA), and myotonic dystrophy, all of which manifest symptoms such as progressive muscle weakness and atrophy. Recent advancements in genetic diagnostics, particularly whole-exome sequencing, have significantly enhanced the accuracy of diagnoses and facilitated the development of personalized treatment strategies, which are crucial for improving patient outcomes. Innovative therapeutic approaches, such as gene therapy and CRISPR-Cas9 technology, hold considerable potential for rectifying genetic anomalies and creating targeted treatment options. Current research endeavors aim to expand our comprehension of the underlying mechanisms of these disorders, with particular emphasis on inflammation and cellular repair mechanisms. As our understanding evolves, there is optimism for the emergence of more effective therapeutic interventions, ultimately leading to an improved quality of life for individuals affected by these complex conditions.